I-Mab (NASDAQ:NBP) SVP Cong Claire Xu Sells 3,494 Shares

I-Mab (NASDAQ:NBP) SVP Cong Claire Xu sold 3,494 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $3.94, for a total transaction of $13,766.36. Following the completion of the sale, the senior vice president directly owned 290,154 shares in the company, valued at approximately $1,143,206.76. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

I-Mab Stock Performance

NASDAQ NBP remained flat at $1.71 during trading hours on Tuesday. 756,514 shares of the company were exchanged, compared to its average volume of 894,712. The company has a market capitalization of $197.76 million, a P/E ratio of -4.75 and a beta of 1.48. I-Mab has a 12-month low of $1.28 and a 12-month high of $6.79. The business’s fifty day simple moving average is $2.27.

I-Mab (NASDAQ:NBP) last released its quarterly earnings results on Wednesday, April 8th. The company reported ($0.30) earnings per share (EPS) for the quarter. As a group, analysts anticipate that I-Mab will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On I-Mab

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. Hedge funds and other institutional investors own 38.38% of the company’s stock.

Analyst Ratings Changes

NBP has been the topic of several analyst reports. Weiss Ratings cut shares of I-Mab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 18th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of I-Mab in a research note on Wednesday, April 8th. Finally, Wall Street Zen cut shares of I-Mab from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.00.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.